Xenograft models have long been the gold standard method for preclinically assessing the relationship between PK/PD and efficacy. However,
CN Bio opens new laboratory facilities to extend Organ-on-a-chip contract research services capabilities
State-of-the-art laboratories significantly expand project capacity to meet increasing market demand for Organ-on-a-Chip research services Cambridge,
MPS World Summit Round-up
If you could not attend the inaugural Microphysiological System (MPS) World Summit in New Orleans earlier this month, but it is on
CN Bio appoints Dr Paul Brooks as Chief Business Officer
Cambridge, UK, 24 May 2022: CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ
CN Bio introduces PhysioMimix NASH ‘in-a-box’ reagent kit
First product within new ‘in-a-box’ range, which harnesses next-generation, human-relevant Liver-on-a-Chip technology to improve the accuracy and
The lung in crisis: fighting back against pathogens, infections and inflammation with predictive in vitro lung models that accelerate drug discovery
The human lung is in crisis Our lungs represent the only internal organ that is directly subject to the environment and therefore face a relentless
Debunking the 9 Myths of Organ-on-a-Chip Technology
Organ-on-a-chip (OOC) technology offers you a transformative approach to better science. By bridging the gaps between traditional cell culture, animal
De-risking drug-induced liver injury through the predictive power of organ-on-a-chip
The liver is responsible for metabolizing most medications, and as such represents one of the primary tissues affected by adverse drug reactions.
PhysioMimix™ Multi-Organ Microphysiological System selected by The Scientist as a ‘Top 10 Innovation 2021′
Next generation Organ-on-a-Chip technology listed second in Top 10 Innovations for 2021 System enables pre-clinical studies that simulate complex